{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,11]],"date-time":"2024-08-11T00:28:19Z","timestamp":1723336099782},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,10]]},"DOI":"10.7759\/cureus.66569","type":"journal-article","created":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T12:42:57Z","timestamp":1723293777000},"source":"Crossref","is-referenced-by-count":0,"title":["Certolizumab-Induced Liver Injury in Ankylosing Spondylitis: A Case Report and Causality Assessment"],"prefix":"10.7759","author":[{"given":"Imane","family":"Bensaghir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Latifa","family":"Tahiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Farih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanan","family":"Rkain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fadoua","family":"Allali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(11)60071-8","article-title":"Spondyloarthritis","volume":"377","author":"Dougados M","year":"2011","unstructured":"Dougados M, Baeten D. Spondyloarthritis. Lancet. 2011, 377:2127-37. 10.1016\/s0140-6736(11)60071-8","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde D","year":"2017","unstructured":"van der Heijde D, Ramiro S, Landew\u00e9 R, et al.. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017, 76:978-91. 10.1136\/annrheumdis-2016-210770","journal-title":"Ann Rheum Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17010014","article-title":"RUCAM in drug and herb induced liver injury: the update","volume":"17","author":"Danan G","year":"2015","unstructured":"Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2015, 17:14. 10.3390\/ijms17010014","journal-title":"Int J Mol Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.12.025","article-title":"Liver injury from tumor necrosis factor-\u03b1 antagonists: analysis of thirty-four cases","volume":"11","author":"Ghabril M","year":"2013","unstructured":"Ghabril M, Bonkovsky HL, Kum C, et al.. Liver injury from tumor necrosis factor-\u03b1 antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol. 2013, 11:558-564.e3. 10.1016\/j.cgh.2012.12.025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.02.006","article-title":"Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland","volume":"144","author":"Bj\u00f6rnsson ES","year":"2013","unstructured":"Bj\u00f6rnsson ES, Bergmann OM, Bj\u00f6rnsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013, 144:1419-25, 1425.e1-3; quiz e19-20. 10.1053\/j.gastro.2013.02.006","journal-title":"Gastroenterology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.07.062","article-title":"Risk of drug-induced liver injury from tumor necrosis factor antagonists","volume":"13","author":"Bj\u00f6rnsson ES","year":"2015","unstructured":"Bj\u00f6rnsson ES, Gunnarsson BI, Gr\u00f6ndal G, et al.. Risk of drug-induced liver injury from tumor necrosis factor antagonists. Clin Gastroenterol Hepatol. 2015, 13:602-8. 10.1016\/j.cgh.2014.07.062","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17020224","article-title":"Hepatotoxicity by drugs: the most common implicated agents","volume":"17","author":"Bj\u00f6rnsson ES","year":"2016","unstructured":"Bj\u00f6rnsson ES. Hepatotoxicity by drugs: the most common implicated agents. Int J Mol Sci. 2016, 17:224. 10.3390\/ijms17020224","journal-title":"Int J Mol Sci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-009-0342-4","article-title":"Infliximab-related hepatitis: discussion of a case and review of the literature","volume":"5","author":"Mancini S","year":"2010","unstructured":"Mancini S, Amorotti E, Vecchio S, Ponz de Leon M, Roncucci L. Infliximab-related hepatitis: discussion of a case and review of the literature. Intern Emerg Med. 2010, 5:193-200. 10.1007\/s11739-009-0342-4","journal-title":"Intern Emerg Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-005-0169-y","article-title":"Serious liver disease induced by infliximab","volume":"26","author":"Tobon GJ","year":"2007","unstructured":"Tobon GJ, Ca\u00f1as C, Jaller JJ, Restrepo JC, Anaya JM. Serious liver disease induced by infliximab. Clin Rheumatol. 2007, 26:578-81. 10.1007\/s10067-005-0169-y","journal-title":"Clin Rheumatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200626110-00008","article-title":"Onset of liver damage after a single administration of infliximab in a patient with refractory ulcerative colitis","volume":"26","author":"Ierardi E","year":"2006","unstructured":"Ierardi E, Valle ND, Nacchiero MC, De Francesco V, Stoppino G, Panella C. Onset of liver damage after a single administration of infliximab in a patient with refractory ulcerative colitis. Clin Drug Investig. 2006, 26:673-6. 10.2165\/00044011-200626110-00008","journal-title":"Clin Drug Investig"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-009-1179-y","article-title":"Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercept","volume":"28","author":"Carlsen KM","year":"2009","unstructured":"Carlsen KM, Riis L, Madsen OR. Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercept. Clin Rheumatol. 2009, 28:1001-3. 10.1007\/s10067-009-1179-y","journal-title":"Clin Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.gcb.2010.01.016","article-title":"Infliximab-induced acute hepatitis during Crohn's disease therapy: absence of cross-toxicity with adalimumab","volume":"34","author":"Haennig A","year":"2010","unstructured":"Haennig A, Bonnet D, Thebault S, Alric L. Infliximab-induced acute hepatitis during Crohn's disease therapy: absence of cross-toxicity with adalimumab. Gastroenterol Clin Biol. 2010, 34:e7-8. 10.1016\/j.gcb.2010.01.016","journal-title":"Gastroenterol Clin Biol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2023-256879","article-title":"Certolizumab-induced liver injury: as assessed for causality by the updated RUCAM","volume":"16","author":"Shakhashiro M","year":"2023","unstructured":"Shakhashiro M, Crasta R, Javed F. Certolizumab-induced liver injury: as assessed for causality by the updated RUCAM. BMJ Case Rep. 2023, 16:10.1136\/bcr-2023-256879","journal-title":"BMJ Case Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/279685-certolizumab-induced-liver-injury-in-ankylosing-spondylitis-a-case-report-and-causality-assessment","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T12:43:00Z","timestamp":1723293780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/279685-certolizumab-induced-liver-injury-in-ankylosing-spondylitis-a-case-report-and-causality-assessment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,10]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.66569","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,10]]}}}